Skip to content
DaveManuel.com · Institutional Ownership · 13F Holdings

Squadron Capital Management LLC

Reported holdings as of Q2 2026, from 3 quarterly filings.

CIK
2050709
Reported value
$322.2M
Positions
38
Top 10 weight
67.8%
Filed
2026-08-14
Days after quarter end
45

Holdings

Download these holdings as CSV

SecurityTickerValue SharesWeightWeight change Held Change
RELMADA THERAPEUTICS INCRLMD$50.9M7,350,00015.78%-5.83pp3q-13.3%-$7.8M
C4 THERAPEUTICS INC CALLCCCC$35.5M7,200,00011.01%+8.85pp2q+220.0%+$24.4M
COGENT BIOSCIENCES INCCOGT$33.5M865,00010.39%-0.72pp3q+9.8%+$3.0M
ZENTALIS PHARMACEUTICALS INC CALLZNTL$20.0M3,700,0006.21%+2.75pp2q+1.9%+$373.2K
KODIAK SCIENCES INCKOD$19.5M500,0006.05%+0.74pp3q+31.6%+$4.7M
RELAY THERAPEUTICS INCRLAY$18.1M970,0005.63%+2.63pp2q+44.2%+$5.6M
EDGEWISE THERAPEUTICS INCEWTX$11.8M290,0003.66%-0.38pp3q-17.1%-$2.4M
MAZE THERAPEUTICS INCMAZE$10.0M335,0003.10%+0.29pp3q+30.1%+$2.3M
BIOAGE LABS INC CALLBIOA$9.9M155,0003.08%-newNEW
INVENTIVA SAIVA$9.2M2,435,0002.86%+1.77pp3q+355.1%+$7.2M
ADLAI NORTYE LTDANL$8.8M764,8762.73%-0.48pp2q-39.5%-$5.8M
COMPASS PATHWAYS PLC CALLCMPS$8.6M300,0002.66%-newNEW
ENLIVEN THERAPEUTICS INCELVN$8.1M160,0002.52%-newNEW
REZOLUTE INC CALLRZLT$6.8M403,4102.10%-newNEW
ARRIVENT BIOPHARMA INC CALLAVBP$6.4Moptions only1.97%+1.04pp3qOPTIONS
PALISADE BIO INC COMPALI$6.3M3,000,0001.95%+0.02pp3qHELD
INHIBIKASE THERAPEUTICS INCIKT$6.1M3,000,0001.89%-0.26pp3q-14.3%-$1.0M
Adagene IncADAG$5.2M1,250,0001.63%-newNEW
FORTE BIOSCIENCES INCFBRX$4.8M225,0001.48%-newNEW
INFLARX NVIFRX$4.5M2,000,0001.39%-newNEW
ASSEMBLY BIOSCIENCES INCASMB$4.4M160,0001.36%-newNEW
PROMIS NEUROSCIENCES INCPMN$4.3M324,9771.33%-0.19pp2qHELD
CONTINEUM THERAPEUTICS INCCTNM$4.3M260,0001.32%-newNEW
DEFINIUM THERAPEUTICS INCDFTX$4.0M85,0001.24%-newNEW
SOL GEL TECHNOLOGIESSLGL$3.9M52,0001.20%+0.30pp2q+67.7%+$1.6M
SCYNEXIS INC COMSCYX$3.1M756,8840.96%-newNEW
ProQR Therapeutics BV (NetherlPRQR$2.8M1,511,4960.87%-newNEW
DISC MEDICINE INC CALLIRON$2.2Moptions only0.68%-newOPTIONS
LIPOCINE INC NEW COM NEWLPCN$2.1M810,0000.64%-0.67pp3q+80.0%+$921.6K
ULTRAGENYX PHARMACEUTICAL IN CALLRARE$1.8Moptions only0.57%-newOPTIONS
CUE BIOPHARMA INCCUE$1.6M50,0000.49%-newNEW
CALCIMEDICA INCCALC$1.3M1,244,8640.40%-newNEW
QUINCE THERAPEUTICS INC COMIRLA$734.4K40,3750.23%-newNEW
NUVECTIS PHARMA INC CALLNVCT$711.7Koptions only0.22%-newOPTIONS
PASITHEA THERAPEUTICS CORKTTA$515.4K1,000,0000.16%-0.41pp3q-52.4%-$566.9K
INMED PHARMACEUTICALS INC COM NEWINM$503.8K325,0000.16%-newNEW
NEUMORA THERAPEUTICS INC.NMRA$170.0K100,0000.05%-newNEW
NextCure, Inc.NXTC$103.1K64,4640.03%-1.01pp3q-75.7%-$320.9K

By sector

Industry comes from the SIC code on each company's own SEC filings, which is self-reported and sometimes out of date. Derivative exposure is counted with the shares. Securities the SEC assigns no industry - funds, trusts, foreign issues - are shown as not classified rather than dropped.

Biotech & Pharma 98.5%Not classified 1.5%
 
SectorValueShare
Biotech & Pharma$317.5M98.5%
Not classified$4.8M1.5%

What the disclosed book did

This is not the fund's return. A 13F shows long US equity positions only, so shorts, bonds, foreign listings, private holdings and cash are all invisible here. What this measures is the quarter's change in value of the positions this manager disclosed, had they been left untouched - the return a reader following the filing would have earned.

QuarterBookMarket DifferencePriced
Q2 2026+12.6%+14.8%-2.3%86%
Q1 2026+1.7%-4.6%+6.3%98%

Market is SPY over the same two quarter ends, priced the same way as everything else here - the median across every filer reporting it. It is a large-cap US proxy, so a manager holding small caps or biotech will beat or trail it for reasons that are not skill. Prices are quarter-end to quarter-end and say nothing about the path in between, or about trades opened and closed inside a quarter.

Quarter by quarter

QuarterValuePositions NewAddedTrimmed ExitedTop 10 Days to file
Q2 2026$322.2M3820961567.8%45
Q1 2026$272.9M3315871569.9%45
Q4 2025$236.0M33000065.7%48

Rows marked UNVERIFIED ID, PLACEHOLDER ID, TICKER AS ID or NON-CUSIP ID carry an identifier that is not a valid CUSIP. They are shown because the filer reported that money, but treat the security named with caution - hover the chip for what is wrong with it, and see the methodology.

Held counts consecutive filings in which this manager reported the position, and can reach further back than the quarters listed above: the tabs begin at Q4 2018 because earlier coverage is too sparse to describe a market, but tenure is counted over every filing we hold, some reaching to 2007. A position sold and later rebought starts again from one.

Weight change is the shift in this position's share of the whole book, in percentage points. It is the more useful column: when money flows into or out of a broad fund, almost every holding is bought or sold at once, so added and trimmed largely track flows. A weight that rose while the book shrank is a decision. Both compare with the previous quarter this filer reported, not the previous calendar quarter.